Activity in the Gastrointestinal Tract after Administration of Bone-Seeking Radiopharmaceuticals

Purpose: To test the possibility that (radio)activity of non-pertechnetate nature is excreted into the gastrointestinal tract at bone scintigraphy. Material and Methods: The distribution of a bone-seeking radiopharmaceutical (99mTc-HDP) was studied in an experimental mouse system by dissecting different organs and assessing their activity with a gamma-counter. Results: A comparison of the activity of the submandibular glands, which are assumed to accumulate only pertechnetate, and the gastrointestinal tract showed that a significant fraction of the activity excreted into the gastrointestinal tract did not consist of pertechnetate. Part of the excretion took place in the stomach. It was not connected to a specific bone-seeking agent or 99Mo/99mTc generator. Nor did it increase with time between make-up and injection. The excretion of the non-pertechnetate acitvity was reduced by cimetidine and omeprazole. These gastric-secretion blocking drugs did not reduce excretion of pertechnetate or significantly affect the general distribution of the radiopharmaceutical. Conclusion: There is a significant excretion of non-pertechnetate activity in the gastrointestinal tract. Part of this may be caused by excretion of the undegraded radiopharmaceutical by the stomach mucosa.

[1]  H. Jacobsson,et al.  Disturbances of fluid balance reduce the image quality of bone scintigraphy. Experimental studies in mice , 1994, Nuclear medicine communications.

[2]  V. Ho,et al.  Extraosseous Tc-99m MDP uptake: a pathophysiologic approach. , 1993, Radiographics : a review publication of the Radiological Society of North America, Inc.

[3]  M. Festing,et al.  The scope for improving the design of laboratory animal experiments , 1992, Laboratory animals.

[4]  H. Jacobsson,et al.  Effect of size fractionation on the distribution of an albumin colloid in the reticuloendothelial system of the mouse. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[5]  J. Perry,et al.  Radiopharmaceuticals in Nuclear Medicine Practice , 1987 .

[6]  H. Gray.  Soft Tissue Uptake of Bone Agents , 1987 .

[7]  E. Pauwels.  Tc 99m Bone Seeking Phosphate Compounds: Studies on In Vivo and In Vitro Behaviour , 1986 .

[8]  J. Steber,et al.  Properties of hydroxyethane diphosphonate affecting its environmental fate: Degradability, sludge adsorption, mobility in soils, and bioconcentration , 1986 .

[9]  B. Arant.  Renal handling of calcium and phosphorus in normal human neonates , 1983 .

[10]  B. Rhodes,et al.  Drug-induced changes in the biologic distribution of radiopharmaceuticals. , 1982, Seminars in nuclear medicine.

[11]  M. A. Wilson.  The effect of age on the quality of bone scans using technetium-99m pyrophosphate. , 1981, Radiology.

[12]  T. Chaudhuri.  Liver uptake of /sup 99m/Tc--diphosphonate , 1976 .

[13]  T. Chaudhuri.  Liver uptake of 99mTc-diphosphonate. , 1976, Radiology.

[14]  Merrick Mv,et al.  Review article-Bone scanning. , 1975 .

[15]  M. Merrick,et al.  Review article-Bone scanning. , 1975, The British journal of radiology.